Quanta Pharma PT-141 10mg

, also known as

Bremelanotide

, is a pharmaceutical-grade

melanocortin receptor agonist peptide

, researched extensively for its central nervous system action on arousal pathways in both sexes. This lyophilised vial from

Quanta Pharma

offers researchers a high-purity compound for advanced studies in libido research, melanocortin pathway activation, hypoactive sexual desire disorder (HSDD) models, and related CNS-mediated research. Independent Analiza Białek testing confirms the finished vial at 10.06mg content and 99% purity. Available for

UK delivery

with fast dispatch.

Analiza Białek Finished Product Verified

Independent testing of the sealed vial by a leading EU laboratory

Actual Content

Label Claim

Accuracy

Purity

Sample:

Sealed production vial  |

Order:

100014032  |

Tested:

April 2026  |

Verification Key:

8NS7R12B

Quanta Pharma PT-141 Specifications

Peptide

PT-141

Also Known As

Bremelanotide, Vyleesi

Dosage

10mg/vial

Class

Melanocortin Agonist

Structure

7 Amino Acids

Form

Lyophilised

Half-Life

~2.7 Hours

Storage

2-8°C

PT-141 10mg

Quanta Pharma

Quanta Pharma PT-141 Research Benefits

Central nervous system mechanism

: Acts directly on melanocortin receptors in the brain, making it a distinct research tool from peripheral vascular compounds such as PDE5 inhibitors

Dual-sex research applicability

: Researched in both male and female subjects, with FDA approval (as Bremelanotide, brand name Vyleesi) specifically for premenopausal HSDD in women

MC3R and MC4R activation

: Selectively activates the MC3 and MC4 melanocortin receptor subtypes in the hypothalamus and limbic system

Acute, short-duration profile

: Approximately 2.7 hour half-life allows for precisely timed research windows without prolonged receptor occupancy

Independent of vascular function

: CNS-mediated action means research applicability is not limited by the vascular or endothelial status of subjects

Extensively studied heptapeptide

: Derived from melanotan-2 with the skin-pigmenting activity stripped out, leaving the arousal-pathway action intact

How Quanta Pharma PT-141 Works

PT-141

Quanta Pharma PT-141

Because of this CNS mechanism,

Quanta Pharma PT-141

has drawn interest in research populations where vascular compounds are either insufficient or unsuitable, and in female research models where PDE5 inhibitors have no meaningful activity. Its approval as Bremelanotide (brand name Vyleesi) for hypoactive sexual desire disorder in premenopausal women was based on this novel, centrally-acting pharmacological profile.

Quanta Pharma PT-141 vs PDE5 Inhibitors

PT-141

and PDE5 inhibitors represent two entirely different approaches in arousal research. PDE5 inhibitors act peripherally on the vascular system by blocking the enzyme phosphodiesterase-5, enabling a vascular response to an existing stimulus.

Quanta Pharma PT-141

Why Choose Quanta Pharma PT-141?

Quanta Pharma

is renowned for producing pharmaceutical-grade peptides with exceptional purity and accurate dosing. The 10mg vial of

Quanta Pharma PT-141

⚠️ FOR LABORATORY RESEARCH USE ONLY

NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE

Safety Classification:

For use by qualified research personnel only. Keep detailed records of usage and storage as per UK research regulations.

Legal Notice:

This product is exclusively intended for in vitro laboratory research conducted in controlled environments by qualified research staff. It is not for pharmaceutical, domestic, or any other applications. The purchaser accepts that acquiring and using this material is governed by all relevant UK regulations concerning research chemicals.